EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib

Chae A Kim, Mijin Kim, Meihua Jin, Hee Kyung Kim, Min Ji Jeon, Dong Jun Lim, Bo Hyun Kim, Ho-Cheol Kang, Won Bae Kim, Dong Yeob Shin, Won Gu Kim

Endocrinology and Metabolism · 2024

DOI: 10.3803/enm.2023.1854 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Endocrinology and Metabolism, 2024. Verfasst von Chae A Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Phenylurea Compounds, Thyroid Neoplasms, Quinolines, Iodine Radioisotopes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Asan Institute for Life Sciences, Asan Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammatory biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR), serve as valuable prognostic indicators in various cancers. This multicenter, retrospective cohort study assessed the treatment outcomes of lenvatinib in 71 patients with radioactive iodine (RAI)-refractory thyroid cancer, considering the baseline inflammatory biomarkers.

Methods

This study retrospectively included patients from five tertiary hospitals in Korea whose complete blood counts were available before lenvatinib treatment. Progression-free survival (PFS) and overall survival (OS) were evaluated based on the median value of inflammatory biomarkers.

Results

No significant differences in baseline characteristics were observed among patients grouped according to the inflammatory biomarkers, except for older patients with a higher-than-median NLR (≥2) compared to their counterparts with a lower NLR (P= 0.01). Patients with a higher-than-median NLR had significantly shorter PFS (P=0.02) and OS (P=0.017) than those with a lower NLR. In multivariate analysis, a higher-than-median NLR was significantly associated with poor OS (hazard ratio, 3.0; 95% confidence interval, 1.24 to 7.29; P=0.015). However, neither the LMR nor the PLR was associated with PFS. A higher-than-median LMR (≥3.9) was significantly associated with prolonged OS compared to a lower LMR (P=0.036). In contrast, a higher-than-median PLR (≥142.1) was associated with shorter OS compared to a lower PLR (P=0.039).

Conclusion

Baseline inflammatory biomarkers can serve as predictive indicators of PFS and OS in patients with RAI-refractory thyroid cancer treated with lenvatinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsThyroid NeoplasmsQuinolinesIodine RadioisotopesNeutrophilsHumansFemaleMaleMiddle AgedRetrospective StudiesPrognosisAgedAdultInflammationAntineoplastic AgentsBiomarkers, TumorLymphocytesAged, 80 and overRepublic of KoreaBiomarkers

Stichwörter der Autor:innen

Inflammatory biomarkerLenvatinibLymphocytesMonocytesNeutrophilsThyroid neoplasms

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesIodine RadioisotopesAntineoplastic AgentsBiomarkers, TumorBiomarkers

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Korea.
  • Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.
  • Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Förderung

  • Asan Institute for Life Sciences, Asan Medical Center

Zitieren

APA

Kim, C. A., Kim, M., Jin, M., Kim, H. K., Jeon, M. J., Lim, D. J., Kim, B. H., Kang, H. C., Kim, W. B., Shin, D. Y., & Kim, W. G. (2024). Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib. Endocrinology and Metabolism. https://doi.org/10.3803/enm.2023.1854

Vancouver

Kim CA, Kim M, Jin M, Kim HK, Jeon MJ, Lim DJ, et al. Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib. Endocrinology and Metabolism. 2024. doi:10.3803/enm.2023.1854

BibTeX
@article{Kim2024,
  author = {Kim, Chae A and Kim, Mijin and Jin, Meihua and Kim, Hee Kyung and Jeon, Min Ji and Lim, Dong Jun and Kim, Bo Hyun and Kang, Ho-Cheol and Kim, Won Bae and Shin, Dong Yeob and Kim, Won Gu},
  title = {Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib},
  journal = {Endocrinology and Metabolism},
  year = {2024},
  doi = {10.3803/enm.2023.1854}
}
Kostenlos starten →